A Single Arm Multicentre Study Evaluating Pazopanib in First-line Treatment of Poor-risk Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 14 Jun 2017
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Therapeutic Use
- Acronyms FLIPPER
- Sponsors iOMEDICO AG
- 09 Jun 2017 Planned End Date changed from 1 Sep 2018 to 31 Jul 2017.
- 09 Jun 2017 Planned primary completion date changed from 1 Dec 2017 to 30 Jun 2017.
- 09 Jun 2017 Status changed from recruiting to active, no longer recruiting.